Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome

Related Clinical Trial
A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus cliniMACs HUD for T Cell Depletion Cord Blood Stem Cell Transplantation Study (COBLT) Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency Genetic Basis of Immunodeficiency IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency Sirolimus Prophylaxis for aGVHD in TME SCID Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft Influences on Female Adolescents’ Decisions Regarding Testing for Carrier Status of XSCID Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant EZN-2279 in Patients With ADA-SCID AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID) Patients Treated for SCID (1968-Present) Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China Gene Therapy for ADA-SCID MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim Natural History Study of SCID Disorders Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency SCID Bu/Flu/ATG Study With T Cell Depletion Generalized Neonatal Screening of Severe Combined Immunodeficiencies Neonatal Screening of Severe Combined Immunodeficiencies Gene Therapy for X-linked Severe Combined Immunodeficiency An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Registry Study of Revcovi Treatment in Patients With ADA-SCID Multi-center Clinical Study of Cord Blood Stem Cell Transplantation for SCID

Brief Title

Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome

Official Title

Transplantation of Highly Purified Haploidentical CD133 Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome

Brief Summary

      Treatment for severe combined immunodeficiency (SCID) is a medical emergency. A stem cell
      transplant (immature blood cells that can make other blood cells) from a (MSD) matched
      sibling donor (brother or sister who is a "match" for your child's immune (HLA) type),
      usually results in complete correction of immune function. However, most patients lack a
      matched sibling donor, requiring the use of an alternate donor source.

      Transplantation of cells from haploidentical family donors (typically parents) has resulted
      in immune system correction in the majority of SCID individuals. However, only 65-80% of
      patients survive greater than one year after this procedure. Failure results from
      life-threatening infections, graft versus host disease (GvHD) or post-transplant
      treatment-related effects. Also, for patients that survive beyond one year, B-cell (type of
      blood cell that fights infection) and natural killer cell function (cell that attacks
      infections and cancer cells) frequently fail to work, resulting in the need for long-term
      treatment with intravenous gamma-globulin (IVIg).

      In this study, in an effort to restore the overall cell function in patients with SCID,
      researchers will use a highly purified CD133+ hematopoietic cell graft (stem cell transplant
      without many mature donor white cells, called T-cells) obtained via use of the Miltenyi
      CliniMACS device, a device not FDA approved.
    


Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

To investigate safety issues related to use of haploidentical highly purified CD133+ hematopoietic cells in patients with SCID


Condition

Severe Combined Immunodeficiency

Intervention

Stem cell transplant


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Procedure

Estimated Enrollment

4

Start Date

February 2004

Completion Date

August 2007

Primary Completion Date

August 2007

Eligibility Criteria

        Inclusion Criteria:

          -  Patient with confirmed severe combined immunodeficiency

          -  Two years of age or younger

          -  A suitable matched sibling donor is not available

        Exclusion Criteria:

          -  An available matched sibling donor or a confirmed matched unrelated donor

          -  Patients with DiGeorge syndrome, Zap70, MHC Class II deficiency, or cartilage-hair
             hypoplasia

          -  Patients with a Lansky performance score of less than 10, evidence of HIV or a
             congenital rubella infection or a documented neoplasm

          -  Patients in whom it is not possible to perform a peripheral blood cell harvest on a
             haploidentical family member
      

Gender

All

Ages

N/A - 2 Years

Accepts Healthy Volunteers

No

Contacts

Kimberly Kasow, DO, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00152100

Organization ID

ALSCID



Study Sponsor

St. Jude Children's Research Hospital


Study Sponsor

Kimberly Kasow, DO, Principal Investigator, St. Jude Children's Research Hospital


Verification Date

May 2009